Showing 6421-6430 of 8236 results for "".
- Highly Trafficked Roads Up AD Risk in Kids, Teenshttps://practicaldermatology.com/news/highly-trafficked-roads-up-ad-risk-in-kids-teens/2461772/Traffic-related air pollution may increase children and teen’s risk for atopic dermatitis report researchers at National Jewish Health in Denver, Colo. For the study, researchers reviewed charts of patients 0-18 years of age who had been seen at National Jewish Health i
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr
- News You Can Use: SID Announces New Research Grant Program Focusing on Type 2 Inflammationhttps://practicaldermatology.com/news/news-you-can-use-sid-announces-new-research-grant-program-focusing-on-type-2-inflammation/2461767/The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023
- FDA Nod for Galderma's Restylane Eyelighthttps://practicaldermatology.com/news/fda-nod-for-galdermas-restylane-eyelight/2461760/The U.S. Food and Drug Administration (FDA) approved Restylane Eyelight, a hyaluronic acid (HA) dermal filler for the correction of undereye hollowing, in adults over the age of 21. Restylane Eyelight is formulated with NASHA Technology, which has a firm gel te
- News You Can Use: AARS Launches Social Media Toolkit for #Acne Awareness Monthhttps://practicaldermatology.com/news/aars-launches-social-media-toolkit-for-acne-awareness-month/2461754/The American Acne and Rosacea Society (AARS) has launched a social media toolkit to help dermatology medical professionals who are their members share #acnefacts in recognition of Acne Awareness Month in June, The toolkit is available at acneandrosacea.org/acne-awareness-social- me
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- Castle Biosciences Gives Back for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-gives-back-for-skin-cancer-awareness-month/2461750/Castle Biosciences, Inc. is teaming up with The Sun Bus and The Skin Cancer Foundation to support skin cancer prevention, research, education and advocacy. “At our core, we are passionate about transforming disease management, improving health and making a meaningful difference in
- EULAR News: Amgen's Otzela Cools Inflammation, May Improve CV Health in PsAhttps://practicaldermatology.com/news/eular-news-amgens-otzela-cools-inflammation-may-improve-cv-health-in-psa/2461749/Otezla (apremilast) showed promising results in cooling inflammation and reducing cardiometabolic risk factors in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), in Milan, Italy. The MOSAIC Phase
- American Skin Association, National Council for Skin Cancer Prevention Partner for Sun Safetyhttps://practicaldermatology.com/news/american-skin-association-national-council-for-skin-cancer-prevention-partner-for-sun-safety/2461745/The American Skin Association has partnered with the National Council on Skin Cancer Prevention and its broad coalition of member organizations to designate May 26. 2023 as "Don't Fry Day." "Don't Fry Day is the perfect way to jump start the summer holi
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven